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Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus 
kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma. Because the HBV reverse transcriptase lacks a proofreading function, many HBV genotypes, 
subgenotypes, mutants, and recombinants exist. At least 10 HBV genotypes (HBV-A through J) with distinct geographic 
distributions have been identified; by definition, their complete genomic sequences diverge by more than 8%. HBV 
genotype is increasingly becoming recognized as an important factor in the progression and clinical outcome of HBV-
induced disease. Infections by HBV-C or -D are significantly more likely to lead to cirrhosis and hepatocellular carcinoma 
than are infections by HBV-A or -B. Additionally, the hepatitis B e antigen seroconversion response to standard or 
pegylated interferon is more favorable in patients with HBV-A or -B than in those with HBV-C or -D. However, therapeutic 
responses to nucleos(t)ide analogues are generally comparable among HBV genotypes. In conclusion, genotyping of 
HBV is useful in identifying chronic hepatitis B patients who are at increased risk of disease progression, thereby enabling 
physicians to optimize antiviral therapy for these patients. 
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IntRoDuCtIon
Although safe and effective vaccines for hepatitis B virus 
(HBV) have been available for more than two decades, in-
fection by this organism remains a burden to global public 
health, resulting in 600,000 to 1 million deaths per year 
worldwide [1]. Clinically, HBV infection can manifest in 
acute/fulminant hepatitis or in various chronic conditions, 
including an inactive carrier state, chronic hepatitis, cir-
rhosis, and hepatocellular carcinoma (HCC) [2]. Approxi-
mately 15-40% of HBV carriers who acquire the virus early 
in life eventually develop HBV-related cirrhosis or HCC [3].
Being a virus of the family Hepadnaviridae, HBV is the 
smallest human DNA virus, carrying a genome only 3,200 
nucleotides in length [4]. The partially double-stranded 
circular DNA harbors four overlapping open reading 
frames encoding the S (surface), C (core), P (polymerase), 
and X genes (Fig. 1). Because the viral reverse transcrip-
tase has a high error rate, the HBV genome evolves quickly 
over time, with an estimated nucleotide substitution rate 
of 1.4-3.2 × 10
-5/site per year [4]. This unique replication 
strategy accounts for the majority of the point mutations, 
deletions, and insertions observed in the HBV genome. 
The lengthy evolution of HBV has led to the present ex-
istence of various genotypes, subgenotypes, mutants, re-
combinants, and even quasispecies of HBV [5].256    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
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EpIDEMIology AnD DIsEAsE pRo-
gREssIon of HBV InfECtIon
HBV is endemic in Asia and the Pacific islands, Africa, 
Southern Europe, and Latin America. The community 
prevalence of the HBV surface antigen (HBsAg) encoded 
by gene S ranges from 2 to 20% [1]. In Asian countries, 
the majority of HBV infections are acquired perinatally 
or in early childhood by the age of 2 years through verti-
cal (mother-to-child) transmission; however, horizontal 
transmission is the main route of infection in African and 
Western countries [1]. 
Disease progression in patients with chronic hepatitis B 
varies widely. Several viral factors, including the HBV gen-
otype, viral load, and specific viral mutations, have been 
documented to be strongly associated with disease pro-
gression and outcomes (Table 1). The annual incidence of 
cirrhosis is estimated to be 2-6% in those who test positive 
for the HBV e antigen (HBeAg) and 8-10% in those who 
test negative. The annual incidence of HCC is less than 1% 
for patients without cirrhosis and 2-3% for patients with 
cirrhosis [2,3]. 
 
MolECulAR EpIDEMIology of HBV 
gEnotypEs AnD suBtypEs
Analyses of the divergence of HBV genomic sequences 
has led to the identification of 10 HBV genotypes (A 
through J) and several subtypes, where separate geno-
types and subtypes are defined as strains exhibiting an 
entire genome sequence divergence of more than 8% or 
4-8%, respectively [6]. The geographic distribution of 
HBV genotypes A-H and their subtypes is shown in Table 
2. Genotype A is highly prevalent in sub-Saharan Africa 
(subtype A1), Northern Europe (subtype A2), and Western 
Africa (subtype A3). Genotypes B and C are prevalent in 
the Asian Pacific region. However, the prevalence rates of 
genotypes B and C vary among the different Asian coun-
tries (Table 3) [7]. For example, HBV-C is more common 
than HBV-B in China, Japan, and Korea, whereas HBV-B 
is the more common genotype in Taiwan and Vietnam [8]. 
Of particular note is the fact that almost all chronic hepa-
titis B patients in Korea are infected with HBV-C [7].  
Genotype B has six subtypes, B1-B6. B1 is found in Ja-
pan; B2-B5 and B7 are found in East Asia, and B6 is found 
table 1. Risk factors associated with disease progression in chronic hepatitis B patients
Viral factors Host factors Environmental factors
High viral load Advanced age Aflatoxin exposure 
Genotype (HBV-C > HBV-B; HBV-D > HBV-A) Male gender Alcohol consumption
Basal core promoter mutation
Pre-S deletion 
Genetic alterations
Family history of HCC
Ethnicity (Asian > Caucasian)
Cigarette smoking
Concurrent infection with hepatitis C or   
  D virus or with HIV 
Diabetes mellitus
Obesity
Metabolic syndrome
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus.
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Figure 1. Hepatitis B virus has a partially double-stranded 
circular DNA genome harboring four overlapping open reading 
frames: S, surface gene; C, core gene; P, polymerase gene; X, X 
gene. Kao JH. Molecular epidemiology of HBV     257
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in indigenous populations living in Arctic regions, includ-
ing Alaska, Northern Canada, and Greenland. Genotype 
C, which has subtypes C1-C5, is found primarily in East 
and Southeast Asia. Genotype D, which has subtypes D1-
D5, is prevalent in Africa, Europe, the Mediterranean 
region, and India. Genotype E is restricted to West Africa. 
Genotype F, which has 4 subtypes (F1-F4), is found in Cen-
tral and South America. Genotype G has been reported 
in France, Germany, and the United States. Genotype H 
is found in Central America [9,10]. Recently, genotype I 
was isolated in Vietnam and Laos [11], and genotype J was 
identified in Japan [12].
HBV gEnotypE AnD DIsEAsE pRo-
gREssIon In pAtIEnts wItH CHRonIC 
HEpAtItIs B 
Current evidence for the impact of HBV genotype on the 
short- and long-term adverse outcomes of chronic HBV in-
fection is summarized in Table 4. Most retrospective and 
case-control studies have indicated that patients infected 
with HBV-C have more severe liver disease, including 
cirrhosis and HCC, than those with infected with HBV-B 
[2,8,13]. In a recent community-based prospective cohort 
study of 2762 Taiwanese HBV carriers, HBV-C was as-
sociated with a higher risk of HCC than was HBV-B; the 
adjusted hazard ratio was 2.35 (95% confidence interval 
[CI], 1.68 to 3.30; p < 0.001) [14]. These findings confirm 
that HBV-C is associated with a higher risk of HCC devel-
opment than HBV-B is. 
HBV genotype also affects the clinicopathologic features 
of patients with resectable HCC. Of 193 patients with re-
sectable HBV-related HCC in Taiwan, those infected with 
HBV-B had a higher rate of solitary tumor than did those 
infected with HBV-C (94% vs. 86%; p = 0.048), but they 
also had more satellite nodules (22% vs. 12%; p = 0.05). 
These features may contribute to the recurrence patterns 
and prognosis of HBV-related HCC patients infected with 
HBV-B or -C infection [15,16]. Death related to liver dis-
ease occurs more often in patients with HBV-D and -F 
than in those with HBV-A [17,18].
The importance of HBV genotype on the development 
of HCC has prompted the recent development of a clinical 
HBV scoring system, a nomogram including several inde-
pendent risk predictors, including sex, age, family history 
of HCC, alcohol consumption, serum alanine aminotrans-
ferase (ALT) level, HBeAg status, serum HBV DNA level, 
and HBV genotype [19]. Based on clinical characteristics 
that can be determined noninvasively, this easy-to-use no-
mogram has been found to accurately predict HCC risk in 
HBV-infected persons and could facilitate communication 
between physicians and their patients, particularly in the 
Asian Pacific region. 
table 2. geographic distribution of HBV genotypes 
and subtypes
Genotype Subtype Geographic location
A A1 Sub-Saharan Africa
A2 Northern Europe
A3 Western Africa
B B1 Japan
B2-B5 Taiwan, China, Indonesia, Vietnam, 
   Philippines
B6 Alaska, Northern Canada, Greenland
C C1-C3 Taiwan, China, Japan, Korea, Southeast
   Asia
C4 Australia
C5 Philippines, Vietnam
D D1-D5 Africa, Europe, Mediterranean basin, 
   India
E Restricted to West Africa
F F1-F4 Central and South America
G France, Germany, United States
H Central America
I Laos, Vietnam
J Japan
table 3. Distribution of hepatitis B virus (HBV) geno-
types in different Asian countries
Prevalence (%) of HBV genotype
Country       A B C D Others
China  2 41 53 1 1
Hong Kong 0 33 63 0 4
Japan  2 12 85 0 1
Korea 0 0 100 0 0
Philippines 51 22 27 0 0
Solomon 0 0 55 45 0
Taiwan 3 71 22 0 4
Thailand 1 12 87 0 0
Vietnam 22 12 30 24 12258    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
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MolECulAR MECHAnIsMs of HBV 
gEnotypE-spECIfIC pAtHogEnEsIs
The pathogenic differences among various HBV geno-
types have been partially clarified. Intracellular expres-
sion levels of HBV DNA and HBV core antigen (HBcAg), 
as well as the extracellular levels of HBV DNA and HBeAg, 
have been found to be higher for HBV-B and -C genotypes 
than for HBV-A and -D. The intracellular accumulation 
of HBV DNA and viral antigens may play a role in induc-
ing liver cell damage. Additionally, the higher replication 
capacity of the C genotype may explain why it is the geno-
type associated with the most severe HBV-induced liver 
disease [20,21].
In recent in vitro studies, we found that; 1) the expres-
sion of intracellular HBV core protein increased in strains 
of the C genotype when mutations were made in the 
precore or basal core promoter regions affecting HBeAg 
expression; 2) the expression of intracellular HBV surface 
protein was lower for a precore wild-type HBV-C strain 
than for HBV-B; 3) the precore mutation was associated 
with a decreased level of extracellular HBV DNA; 4) less 
HBsAg was secreted by HBV-C than by HBV-B; and 5) less 
HBeAg was secreted by HBV-B than by HBV-C [22]. The 
in vivo and in vitro manifestations of HBV-B and -C are 
compared in Table 5.
HBV gEnotypE AnD AntI-VIRAl 
tREAtMEnts
Interferon-based therapy
The therapeutic endpoints for the management of 
chronic hepatitis B include sustained suppression of the 
HBV DNA level, normalization of the serum ALT level, his-
tologic improvement, HBeAg clearance or seroconversion 
(for HBeAg-positive patients), and HBsAg clearance or 
seroconversion [23]. Two types of drug therapy are in cur-
rent use for HBV treatment: interferon (IFN)-a, which is 
used in both standard and pegylated forms, and nucleos(t)-
ide analogues, including lamivudine, telbivudine, enteca-
vir, adefovir dipivoxil, and tenofovir disoproxil furamate 
[6-8].
Recent studies have suggested that HBV genotype af-
fects the therapeutic response to both IFN and nucleos(t)-
ide analogue-based agents [23,24]. In brief, the incidence 
of sustained ALT normalization and HBeAg seroconver-
sion 6-12 months after the cessation of interferon treat-
ment is significantly higher in patients with HBV-A and -B 
than in those with HBV-C or -D [25,26]. In Asian HBeAg-
positive patients, those with HBV-B are susceptible to 
both standard and pegylated IFN, and those with HBV-C 
are more likely to respond favorably to pegylated IFN than 
to standard IFN [27-31]. Additionally, the incidence of 
durable HBeAg clearance 3 years after the cessation of pe-
gylated IFN-a treatment is higher in patients with HBV-A 
or -B than in those with HBV-C or -D [32]. 
In the absence of a cure for chronic HBV infection, the 
desired endpoint in current management of this disease is 
the complete suppression of HBsAg expression. In a long-
term follow-up study of HBeAg-negative patients treated 
with pegylated IFN, patients infected with HBV-A had a 
significantly higher mean incidence of HBsAg clearance 
(20%) than those infected with HBV-B, -C, or -D (mean 
clearance rates of 6, 9, and 6%, respectively) [33]. Addi-
tionally, the kinetics of HBsAg clearance during pegylated 
table 4. Associations between hepatitis B virus (HBV) genotypes and markers of disease progression in patients 
with chronic HBV infection   
Genotypes compared B vs. C
a A vs. D
a
B C A D
Timing of HBeAg seroconversion  Earlier Later Earlier Later
Incidence of HBsAg seroclearance  Higher Lower Higher Lower
Severity of liver histology  Lower Higher Lower Higher
Incidence of progression to cirrhosis and 
  hepatocellular carcinoma
Lower Higher Lower Higher
HBeAg, HBV e-antigen; HBsAg, HBV surface antigen.
aBecause of the unique distribution of HBV genotypes in Asian and Western countries, sufficient data for meaningful comparisons are 
available only for comparisons between genotypes B and C or betweens genotype A and D.Kao JH. Molecular epidemiology of HBV     259
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IFN treatment varied among the different HBV genotypes. 
For example, at the end of treatment, the mean decline in 
HBsAg levels was greatest in patients with HBV-A, inter-
mediate in those with HBV-B or -D, and least in those with 
HBV-C or -E; during the follow-up period, the serum HB-
sAg level continued to decrease in the patients with HBV-
A or -D, whereas HBsAg rebound was observed in those 
with HBV-B, -C, or -E [34]. 
A recent meta-analysis confirmed that patients infected 
with HBV-A respond better to IFN-a treatment than do 
those infected with HBV-D, regardless of the patient’s 
HBeAg status, and that HBeAg-positive patients infected 
with HBV-B respond better to IFN-a treatment than do 
HBeAg-positive patients infected with HBV-C [35]. There-
fore, patients with HBV-A or -B infection generally have a 
better response to IFN-a than do those with HBV-C or -D 
infection [36]. The data pooled from the two largest global 
trials of HBeAg-positive patients treated with pegylated 
IFN demonstrate that HBV-A patients with a higher ALT 
level or a lower HBV DNA level and HBV-B and -C patients 
with both a higher ALT level and a lower HBV DNA level 
have a high predicted probability of a sustained response 
and should be considered for IFN therapy. On the other 
hand, HBV-D patients have the lowest chance of sustained 
response, irrespective of their ALT or HBV DNA levels; 
IFN therapy is thus not recommended for these patients 
[37]. 
therapy with nucleoside or nucleotide analogues   
In most clinical studies, the therapeutic responses to 
lamivudine, adefovir, entecavir, and telbivudine have been 
similar among the different HBV genotypes [5,8,23,24], 
and a recent meta-analysis found no significant association 
between HBV genotype and the response to nucleos(t)-
ide analogues [35]. Although HBV genotypes seem to have 
little impact on the response to nucleos(t)ide analogue 
treatment [36], our retrospective analysis has suggested 
that genotype B is independently associated with earlier 
detection of lamivudine resistance. Additionally, we found 
that the development of lamivudine resistance within the 
first 12 months of lamivudine therapy had a significantly 
higher association with genotype B than with genotype 
C (odds ratio, 8.27; p = 0.004) [38]. Therefore, more fre             
quent monitoring of genotypic resistance might be needed 
for specific HBV genotypes during nucleos(t)ide analogue 
therapy. 
Complete clearance of HBsAg is rare in chronic hepatitis 
B patients treated with oral agents. However, Marcellin et 
al. [39] recently reported that complete HBsAg clearance 
occurred in five of 158 HBeAg-positive patients after 48 
weeks of treatment with tenofovir disoproxil. Of these five 
Caucasian patients, two were infected with HBV-A, and 
three were infected with HBV-D. Although the proportion 
of patients with HBsAg loss was too small to reach any 
definite conclusions, the association of HBV genotype with 
nucleos(t)ide analogue-induced HBsAg clearance is inter-
esting and deserves further study. 
table 5. In vivo and in vitro manifestations of HBV-B vs. HBV-C
In vivo In vitro  Implications
HBeAg   Longer immune clearance phase 
(in HBeAg-positive patients) for 
HBV-C
More HBeAg secreted for 
   HBV-C
Increased secretion of HBeAg in 
HBV-C leads to a longer immune 
clearance phase for HBV-C 
Earlier HBeAg seroconversion for 
HBV-B
HBsAg  Higher HBsAg titer for HBV-B  More HBsAg secreted for 
   HBV-B
Findings are consistent, but biological 
and clinical significance remain to 
be clarified 
Hepatitis flare after
   spontaneous HBeAg 
   loss
More frequent for HBV-C Increased expression of 
intracellular core protein when 
precore or BCP mutation 
introduced into HBV-C
Increased expression of core protein 
on hepatocyte membrane in HBV-C 
triggers more immune-mediated 
hepatocytolysis
Serum HBV DNA level Comparable between HBV-B and 
HBeAg-positive HBV-C
Extracellular HBV DNA levels 
similar 
Wild-type HBV-B and -C have similar 
replication efficiency 
HBV, hepatitis B virus; HBeAg, HBV e-antigen; HBsAg, HBV surface antigen; BCP, basal core promoter.260    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
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ConClusIons
Investigations of the molecular epidemiology and clini-
cal implications of HBV genotypes have resulted in clini-
cally significant advances over the past decade, particu-
larly with regards to genotypes found in the Asian Pacific 
region. Accumulating evidence [40] suggests that a patient 
with chronic HBV infection should receive HBV genotyp-
ing unless he or she lives in a country known to harbor 
only one HBV genotype. This measure will help practicing 
physicians to identify those patients who are at increased 
risk of disease progression to end-stage liver disease and 
those who can benefit most from interferon-based therapy 
[41,42].
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